STEPHEN J. LERMAN, M.D.; GEORGE A. NANKERVIS, Ph.D., M.D.; ALFRED D. HEGGIE, M.D.; ELI GOLD, M.D.
A controlled double-blind field trial of rubella vaccine (HPV-77:DE-5) was conducted in 150 young, postpuberal females. Arthralgia or arthritis occurred in 39% of the susceptible subjects given vaccine, in 12% of the immune subjects who received vaccine, and in 10% of the placebo recipients. There was no correlation between the occurrence of joint reactions and age (range, 15 to 26 years). One girl had recurrences of joint symptoms for a year after immunization. Seroconversion occurred in 100% of susceptibles but with a mean antibody titer one seventh as high as was observed after natural rubella infection. Subjects with both arthralgia or arthritis and virus excretion developed a significantly higher mean antibody titer than those without either joint reactions or virus excretion. Immune subjects who were given vaccine had neither antibody titer boosts nor virus excretion. The use of rubella vaccine in susceptible postpuberal females entails the risk of joint reactions that may be prolonged.
LERMAN SJ, NANKERVIS GA, HEGGIE AD, GOLD E. Immunologic Response, Virus Excretion, and Joint Reactions with Rubella Vaccine: A Study of Adolescent Girls and Young Women Given Live Attenuated Virus Vaccine (HPV-77:DE-5). Ann Intern Med. ;74:67–73. doi: 10.7326/0003-4819-74-1-67
Download citation file:
Published: Ann Intern Med. 1971;74(1):67-73.
Infectious Disease, Prevention/Screening, Vaccines/Immunization.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use